NetworkNewsBreaks – Marker Therapeutics Inc. (NASDAQ: MRKR) Closes on Public Offering Resulting in $56.5M
Marker Therapeutics (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced that it has closed on an underwritten public offering. The offering was comprised of 32,282,857 shares of its common stock, including an additional 3,710,857 shares based on a partial exercise of the over-allotment option. The announcement noted that the company sold the shares at the public offering price of $1.75 per share. The public offering resulted in gross proceeds of an estimated $56.5 million for the company. Roth Capital Partners acted as…







